110 likes | 118 Views
Explore the results, design, and dosing of Glecaprevir-Pibrentasvir in patients with HIV-HCV coinfection, including baseline characteristics and treatment outcomes. This study offers insights into effective treatment regimens. Discover more at the University of Washington's Hepatitis C Online and Hepatitis Web Study projects.
E N D
Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir in Patients with HIV-HCV CoinfectionEXPEDITION-2 Source: RockstrohJK, et al. Clin Infect Dis. 2018 Mar 16. [Epub ahead of print]
Glecaprevir-Pibrentasvirin HIV-HCV Coinfected PatientsEXPEDITION-2: Study Features Source: RockstrohJK, et al. Clin Infect Dis. 2018 Mar 16. [Epub ahead of print]
Glecaprevir-Pibrentasvirin HIV-HCV Coinfected PatientsEXPEDITION-2: Study Design 0 8 12 20 24 Week GLE-PIB GT 1-6 Non-Cirrhoticn = 137 SVR12 GT 1-6 Cirrhoticn = 16 GLE-PIB SVR12 Abbreviations: GLE-PIB= Glecaprevir-pibrentasvir Drug DosingGlecaprevir-pibrentasvir(100/40 mg) fixed-dose combination: three pills (300/120 mg) once daily Source: Rockstroh JK, et al. Clin Infect Dis. 2018 Mar 16. [Epub ahead of print]
Glecaprevir-Pibrentasvirin HIV-HCV Coinfected PatientsEXPEDITION-2: Baseline Characteristics Source: Rockstroh JK, et al. Clin Infect Dis. 2018 Mar 16. [Epub ahead of print]
Glecaprevir-Pibrentasvirin HIV-HCV Coinfected PatientsEXPEDITION-2: Baseline Characteristics Source: Rockstroh JK, et al. Clin Infect Dis. 2018 Mar 16. [Epub ahead of print]
Glecaprevir-Pibrentasvirin HIV-HCV Coinfected PatientsEXPEDITION-2: Baseline Polymorphisms Source: Rockstroh JK, et al. Clin Infect Dis. 2018 Mar 16. [Epub ahead of print]
Glecaprevir-Pibrentasvirin HIV-HCV Coinfected PatientsEXPEDITION-2: Results EXPEDITION-2: Overall SVR by Analysis 150/153 150/151 ITT = Intent-to-treat; mITT = modified intent-to-treat One GT3 patient with cirrhosis and 85% compliance had on-treatment virologic failure Source: Rockstroh JK, et al. Clin Infect Dis. 2018 Mar 16. [Epub ahead of print]
Glecaprevir-Pibrentasvirin HIV-HCV Coinfected PatientsEXPEDITION-2: Results EXPEDITION-2: Overall SVR by Treatment Regimen 136/136* 14/15 *Excludes one patient with missing data who achieved SVR24 Source: Rockstroh JK, et al. Clin Infect Dis. 2018 Mar 16. [Epub ahead of print]
Glecaprevir-Pibrentasvirin HIV-HCV Coinfected PatientsEXPEDITION-2: Adverse Events Source: Rockstroh JK, et al. Clin Infect Dis. 2018 Mar 16. [Epub ahead of print]
Glecaprevir-Pibrentasvir in HIV-HCV Coinfected PatientsEXPEDITION-2: Conclusions Source: Rockstroh JK, et al. Clin Infect Dis. 2018 Mar 16. [Epub ahead of print]
This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.